Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-15
    E.g., 2018-10-15

Archive Search

7 results
8:20 PM, Aug 16, 2018  |  BC Week In Review | Company News  |  Deals

Almirall acquires U.S. dermatology products from Allergan

cash. The portfolio, which generated 1H18 sales of $70 million, includes acne and inflammation drugs Aczone
12:00 AM, Jul 21, 2008  |  BC Week In Review | Company News  |  Deals

QLT, Allergan deal

Sales LLC subsidiary completed its previously announced acquisition of all worldwide assets related to QLT’s Aczone
dapsone topical gel to treat acne vulgaris for $150 million in cash (see BioCentury, June 16). QLT Inc …
12:00 AM, Jun 16, 2008  |  BC Week In Review | Company News  |  Deals

QLT, Allergan deal

LLC subsidiary paid $150 million in cash to QLT for all worldwide assets related to Aczone
dapsone topical gel to treat acne vulgaris. The topical 5% dapsone gel is approved in the U.S. and …
12:00 AM, Jul 11, 2005  |  BC Week In Review | Company News  |  Deals

QLT, Astellas deal

QLT acquired North American marketing rights to Aczone dapsone topical gel to treat acne from Astellas. QLT now …
which was approved by FDA on July 7. Financial terms were not disclosed. QLT gained Aczone
through its acquisition of Atrix Laboratories Inc. (Fort Collins, Colo.). Atrix co-developed Aczone with Fujisawa Pharmaceutical …
12:00 AM, Jun 21, 2004  |  BC Week In Review | Company News  |  Deals

Atrix, QLT deal

the companies expect to have on the market a 6-month formulation of Eligard and ATRX's Atrisone
5% dapsone topical gel to treat acne. The combined pipeline also will include ATRX's Atrigel sustained-release formulations of …
12:00 AM, Dec 23, 2002  |  BC Week In Review | Company News  |  Deals

Atrix, Fujisawa deal

Fujisawa exercised its option to explore additional indications for ATRX's topical Atrisone dapsone. Under the original …
deal, Fujisawa licensed exclusive North American marketing rights for the acne indication, for which Atrisone is …
in Phase III testing. ATRX has already filed INDs for two additional Atrisone indications, severe itch …
12:00 AM, Aug 12, 2002  |  BC Week In Review | Company News  |  Deals

Atrix, Immune Network deal

to dapsone, an antimicrobial and anti-inflammatory therapeutic. ATRX is in Phase III testing of its Atrisone